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Weaimedtoinvestigatepossiblealterationsincirculatinglevelsoftheperinatalstressmarkershighsensitivity(hs)-CRP,PAI-1,and
S100B—probably reﬂecting brain and adipose tissue inﬂammation—in intrauterine growth-restricted-(IUGR) and appropriate-
for-gestational-age-(AGA) pregnancies, given that these groups diﬀer in fat mass and metabolic mechanisms involving aseptic
inﬂammation. Serum hs-CRP, PAI-1, and S100B levels were measured in 40 mothers, and their 20 AGA and 20 IUGR full-
term fetuses and neonates on postnatal days 1 and 4. hs-CRP, PAI-1, and S100B levels did not diﬀer at all time points between
AGA and IUGR groups. We conclude that the lack of diﬀerence in hs-CRP, PAI-1 and S100B levels, between IUGR and AGA
fetuses/neonates—despite the lower birth weight, reﬂecting reduced fat mass in the former—might indicate more intense adipose
tissue and nervous system inﬂammation in IUGRs. However, implication of other inﬂammation-related mechanisms, common in
the IUGR state (e.g. preeclampsia), cannot be excluded.
1.Introduction
Intrauterine growth restriction (IUGR), a major cause of
infant mortality and morbidity [1, 2], is strongly related to
the later development of the metabolic syndrome in adult
life [3–5]. The metabolic syndrome represents a cluster of
cardiovascular risk factors, such as visceral obesity, lipid and
glucose metabolism abnormalities, leading to type 2 diabetes
mellitus and arterial hypertension [6]. Insulin resistance has
been proposed to be the underlying pathogenic link between
metabolic syndrome and cardiovascular disease [7–9]a n d
is associated with a state of low-grade aseptic inﬂammation
that precedes the onset of metabolic syndrome [10, 11]. Data
suggest that, compared with appropriate for gestational age
(AGA) newborns, those with low birth weight may have
relatively increased visceral fat stores [12, 13], as well as
elevated levels of adipocytokines, such as leptin [14–16]
and visfatin [17], which link the adipose depot to insulin
resistance and sensitivity, respectively, as well as to aseptic
inﬂammation [18].
C-reactive protein (CRP) is considered the major acute-
phase reactant in humans. It is an important ﬁrst-line host
defence molecule, which recognises pathogens and damaged
cells and promotes their elimination by activating the com-
plement system and mediating their phagocytic clearance
[19, 20]. Moreover, using high-sensitivity assays for CRP
(hs-CRP), several studies have shown elevated CRP levels
in obesity, since adiposity resembles a low grade systemic
inﬂammatory state and hs-CRP is released by adipose tissue
[21, 22].
Plasminogen activator inhibitor-1 (PAI-1), secreted by
vascular cells, is the primary physiological inhibitor of
plasminogen activation in blood, contributing to throm-
bus formation [23] .I te i t h e rp r o m o t e so rp r e v e n t sv a s -
cular remodelling processes, such as neointima forma-
tion, atherosclerosis, and pulmonary hypertension [24]. In2 Mediators of Inﬂammation
addition, PAI-1 is produced by adipose tissue [25–27]a n d
macrophages inﬁltrating it [28] and contributes to obesity-
related insulin resistance [25].
S100B is an acidic calcium-binding protein mainly
concentrated in the central nervous system [29]. It has
been reported to regulate several cellular functions (cell
growth,cellstructure,andenergymetabolism)atphysiologic
concentrations, whereas it has been shown to be neurotoxic
in high concentrations [30]. Elevated S100B levels have been
shown to represent a marker of brain damage and hypoxic-
ischemic encephalopathy in asphyxiated infants [31–34],
thus possibly reﬂecting brain and central nervous system
inﬂammation.
Based on the above, we hypothesized that circulating
levels of hs-CRP, PAI-1 and S100B—all markers implicated
in perinatal stress physiology—probably reﬂecting brain
and adipose tissue inﬂammation, might diﬀer in IUGR
compared with AGA pregnancies. Therefore, we aimed to
determine their levels at time-points characteristic for intra-
and extrauterine life.
2.MaterialsandMethods
2.1. Subjects. The study was approved by the Ethics Com-
mittee of our teaching hospital and informed consent
was obtained from participating mothers. Forty parturients
givingconsecutivelybirtheitherto20AGAor20asymmetric
IUGR full-term singleton infants were recruited. Gestational
age was estimated using the date of the last menstrual
period and early antenatal ultrasound. Birth weight was
measured with an electronic scale. Newborns below the third
customized centile for birth weight were deﬁned as IUGR.
For the calculation of the customized centiles, the principles
of the Gestation-Related Optimal Weight (GROW) program
[35, 36] were used. Signiﬁcant determinants of birth weight
(maternal height and booking weight, ethnicity, parity,
gestationalageandgender)wereenteredtoadjustthenormal
birth weight centile limits [35].
In the IUGR group, ﬁve cases resulted from preeclampsia
and seven from pregnancy-induced hypertension. In the
remaining eight cases, the cause of IUGR was unclear; how-
ever, parturients suﬀered from chronic diseases (anaemia,
type 1 diabetes mellitus, cardiac arrhythmias, and thyroidi-
tis). Furthermore, ﬁve of the above mothers were smoking
>10 cigarettes/day during the whole duration of pregnancy.
Doppler studies were performed in the IUGR group
every 10–15 days, starting from the 32nd gestational week.
During each Doppler velocimetry evaluation, three consecu-
tive measurements of the pulsatility index (PI) of the studied
vessel (uterine, umbilical, cerebral arteries) were done and
themeanvaluewasrecorded.Concerninguterineandumbil-
icalarteries[37,38],meanPIvalueswereprogressivelyfound
to be in the upper physiological limits for the corresponding
gestational age in 10 cases (ranging between the 90th and
the 95th percentile), while in the remaining 10 cases PI
values showed increased impedance to ﬂow, being above the
95thpercentileforgestationalage.Regardingmiddlecerebral
arteries [39], Doppler studies showed resistance to be in the
Table 1:Demographicdataofparticipatinginfants(appropriatefor
gestational age-AGA and intrauterine growth restricted-IUGR) and
of their mothers.
AGA
MEAN±SD
IUGR
MEAN±SD P value
Maternal age (years) 31 ±43 1 ±7N S
BMI (pre-pregnancy) 22.0 ±6.12 2 .3 ±6.3N S
Gestational age (weeks) 38.9 ±13 7 .9 ±1.38 .016
Birthweight (g) 3167 ±258 2377 ±262 <.001
Gender N (%) NS
Male 8 (40) 7 (35)
Female 12 (60) 13 (65)
Mode of delivery N (%) NS
Vaginal delivery 9 (45) 9 (45)
Elective caesarean section 11 (55) 11 (55)
lower physiological limits for gestational age, indicating the
initiation of blood ﬂow redistribution process, in order to
spare vital organs (brain, heart, and adrenals). Nevertheless,
amniotic ﬂuid was diminished in all IUGR cases. For the
evaluation of the amniotic ﬂuid, the largest ﬂuid column on
theverticalplanewasassessedandwasdeﬁnedasdiminished
if <2cm. Placental weights were reduced, ranging from 240
to 450g.
In the AGA group, mothers were healthy and were either
non-smokers or abstained from smoking during pregnancy.
Placentas were normal in appearance and weight. Tests for
congenital infections were negative in all women of both
groups and their oﬀspring had no symptoms of intrauterine
infection or signs of genetic syndromes. One- and ﬁve-
minute Apgar scores were ≥8 in all IUGR cases and AGA
controls. The demographic data of participating newborns
and their mothers are listed in Table 1.
2.2. Protocol. Blood was collected from: (i) the mothers
(MS) during the ﬁrst stage of labor, or before receiving
anesthesia in cases of elective caesarean section, (ii) the
doubly clamped umbilical cords (UC-mixed arteriovenous
blood), reﬂecting fetal state, and (iii) the neonates on
postpartum day 1(N1) and 4 (N4), characterizing transition
and stabilization to extrauterine life, respectively. Plasma was
separated by centrifugation and was kept frozen at −80
◦C
until assay.
2.3. Assays. Serum hs-CRP level determination was per-
formed by fully mechanized latex-particle-enhanced im-
munonephelometric assays on the BN ProSpec nephelome-
ter (Dade Behring, Siemens Healthcare Diagnostics, Lieder-
bach, Germany). The intra- and interassay coeﬃcients of
variation (CVs) were less than 6% and 7%, respectively.
PAI-1 levels were measured in citrate plasma with an
enzyme-linkedimmunosorbentassay(Asserachrom PAI-1,
Stago, Asnieres-sur-Seine, France). The minimum detectable
concentration was 1.0ng/mL. The intra- and interassay
coeﬃcients of variation were <6.0% and 7.0%, respectively.Mediators of Inﬂammation 3
Table 2: Signiﬁcant correlations among hs-CRP, PAI-1, S100B and
cortisol levels in IUGR and AGA groups of the MS, UC, N1, and N4
samples.
IUGR AGA
UC PAI-1 versus maternal age r = 0.473, NS
P = .041
MS CORTISOL versus UC
CORTISOL
r = 0.824, r = 0.748,
P<. 001 P<. 001
MS CORTISOL versus UC PAI-1 r =− 0.581, NS
P = .011
UC CORTISOL versus MS S100B r =− 0.494, NS
P = .037
UC CORTISOL versus UC S100B r =− 0.598, NS
P = .009
UC CORTISOL versus UC PAI-1 r =− 0.507, NS
P = .038
Serum S100B protein was analyzed with the use of the
immunoluminometric assay Sangtec 100, (Sangtec Medical
AB, Bromma, Sweden) and was measured by chemilumines-
cence on the LIAISON random access analyzer (DiaSorin,
Saluggia, Italy). Sangtec 100 measures the β-subunit of
S100 as deﬁned by 3 monoclonal antibodies. The minimum
detectable concentration of the assay was 0.02μg/L. The
analysis represents the total amount of S100 and S100B in
the sample, as the assay is speciﬁc for the beta-chain. The
intra-and interassay coeﬃcients of variation for S100B were
less than 3.8 and 5.7%, respectively.
Finally we used data concerning serum levels of the
anti-inﬂammatory agent cortisol which were previously
determined [40].
3.StatisticalAnalysis
Data distribution was tested with the Kolmogorov Smirnov
test. PAI-1, hs-CRP, and S100B levels were not normally
distributed,thusnonparametricprocedures(Mann-Whitney
test, Friedman test, Wilcoxon Sign Rank Test, Spearman
Rank correlation coeﬃcient) were applied in the analysis. P
values <.05 were considered signiﬁcant.
4. Results
Maternal (MS), fetal (UC), day 1 (N1), and day 4 (N4)
neonatal levels of inﬂammatory markers in IUGR cases and
AGA controls are presented in Figures 1, 2,a n d3.
hs-CRPlevelsdidnotdiﬀersigniﬁcantlyatalltimepoints
betweenAGAandIUGRgroups.Inbothgroups,MShs-CRP
was signiﬁcantly higher than UC, N1 and N4 values (P<
.001,P = .012, and P = .001, resp., in the AGA group and
P<. 001, P = .001 and P = .001, resp., in the IUGR group).
UC hs-CRP was signiﬁcantly decreased when compared to
N1 hs-CRP (P <. 001) in the AGA group, and to N1 and N4
hs-CRP (P = .002 and P = .006, resp.,) in the IUGR group.
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Figure 1: Box and whiskers plot presentation of maternal (MS),
fetal (UC), neonatal day 1 (N1), and neonatal day 4 (N4) C-
reactive protein (hs-CRP) levels. Each box represents the median
concentration with the interquartile range. The upper and lower
whiskers represent the range.
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AGA
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Figure 2: Box and whiskers plot presentation of maternal (MS),
fetal (UC), neonatal day 1 (N1), and neonatal day 4 (N4) PAI-
1 levels. Each box represents the median concentration with the
interquartile range. The upper and lower whiskers represent the
range.
PAI-1 levels did not diﬀer signiﬁcantly at all time points
between AGA and IUGR groups. In both groups, MS PAI-14 Mediators of Inﬂammation
0
1
2
3
MS UC N1 N4
AGA
IUGR
S
1
0
0
B
l
e
v
e
l
s
(
μ
g
/
L
)
Figure 3: Box and whiskers plot presentation of maternal (MS),
fetal (UC), neonatal day 1 (N1) and neonatal day 4 (N4) S100B
levels. Each box represents the median concentration with the
interquartile range. The upper and lower whiskers represent the
range.
was signiﬁcantly higher than UC, N1, or N4 PAI-1 (P<
.001,P<. 001, and P = .003, resp., in the AGA and P = .004,
P = .001, and P<. 001, resp., in the IUGR group). No
signiﬁcant diﬀerences were observed among UC, N1 and N4
PAI-1 measurements, either in the AGA or the IUGR group.
S100B levels did not diﬀer signiﬁcantly at all time points
between AGA and IUGR groups. In both groups, MS S100B
was signiﬁcantly lower than UC, N1 and N4 levels (P<. 001,
P<. 001 and P = .001, resp., in the AGA group and P<. 001
in all cases in the IUGR group). In both groups, N1 S100B
was signiﬁcantly increased when compared to respective UC
S100B (P = .004 for both groups).
Statistically signiﬁcant correlations among inﬂammatory
markers and cortisol at all time points in AGA and IUGR
neonates and their mothers are reported in Table 2.T h u s ,
positive correlations were documented between fetal PAI-
1 levels and maternal age (in the IUGR group), as well as
between maternal and fetal cortisol levels (in both groups).
On the other hand, negative correlations were found (in
the IUGR group) between maternal cortisol and fetal PAI-
1 levels, as well as fetal cortisol and maternal/fetal S100B and
fetal PAI-1 levels.
5. Discussion
The results of this study indicate that inﬂammatory markers,
implicated in perinatal stress physiology, such as hs-CRP,
PAI-1 and S100B, determined in the plasma of AGA and
IUGR mother/infant pairs at birth and on postnatal days 1
and 4 did not diﬀer between the two studied groups.
Maternal hs-CRP levels were found signiﬁcantly higher
than fetal and neonatal ones in both studied groups. It
has been previously shown, that maternal CRP values
consistently increase throughout pregnancy as compared to
the nonpregnant state, culminating during labour [41, 42].
Furthermore, it is known that CRP does not cross the
placental barrier [43], justifying the signiﬁcantly lower levels
found in fetuses and neonates.
On the other hand, CRP is a marker of inﬂammation
produced by adipose tissue [21]. Considering that IUGR
babies have by deﬁnition lower amounts of total fat mass
as compared to AGA babies, the lack of diﬀerence in CRP
levelsbetweenthesetwogroups,couldsuggestamoreintense
inﬂammatory state in the adipose tissue of the former. The
gradual increase of CRP in both studied groups from UC
to N1, and N4 could possibly be attributed to adaptational
stress [44–46] to extrauterine life. CRP is produced by pul-
monary alveolar macrophages (PAM), among other immune
response cells [47], and studies in animals have shown the
rapid increase of PAM during postnatal development [48].
Thus, it is possible that the major source of postpartum CRP
production is the constantly increasing PAM population in
the neonatal lung.
Furthermore, we found that in both studied groups,
maternal PAI-1 levels were signiﬁcantly higher than fetal and
neonatal ones. Taken that adipose tissue is an important
source of PAI-1 production [49], this could be attributed to
its higher amounts in adults as compared to neonates.
The lack of diﬀerence in PAI-1 levels between IUGR and
AGA groups could speculatively be attributed, as for CRP, to
a state of more intense adipose tissue-related inﬂammation
in the IUGR, as compared to the AGA neonates. In this
respect, we have previously documented that circulating
levels of the adipocytokines leptin and visfatin are relatively
increased in IUGR neonates, despite their reduced total fat
mass [17, 40]. Moreover, CRP has been shown to induce
PAI-1 expression [50–53]. In addition, other studies have
documented that PAI-1 is mainly produced by visceral fat
[49], which is proportionally higher in the IUGR than the
A G An e o n a t e s[ 12, 13].
However, another explanation could be considered.
Thus, dysfunctional vascular endothelium, characterizing
preeclampsia resulting to IUGR, is associated with increased
PAI-1 release [54]. In this respect, the lack of signiﬁcant
diﬀerences in PAI-1 levels between IUGR and AGA groups
in the present study could possibly rely to the fact that
only ﬁve out of 20 IUGR pregnancies were complicated by
preeclampsia.
Furthermore, smoking in pregnancy, apart from being
ar i s kf a c t o rf o rI U G R[ 55], has a deleterious eﬀect on
vascular endothelium, resulting in endothelial dysfunction,
which again is associated with PAI-1 production [56]. The
factthatPAI-1levelsweresimilarinbothgroupsofthisstudy
could be attributed to the limited number of IUGR mothers
smoking during pregnancy.
In both groups, maternal S100B levels were signiﬁcantly
lower than fetal and neonatal ones (N1 and N4), whileMediators of Inﬂammation 5
N1 S100B levels were signiﬁcantly higher than respective
UC ones. S100B has a neurotrophic eﬀect during both
development and nerve regeneration [57–59]. Respectively,
Gazzolo et al. documented higher S100B concentrations in
children during the ﬁrst year of life and in adolescence, as
compared to adults, thus documenting its neurotrophic role
[57]. This fact might explain on one hand, the low S100B
levels in mothers, and on the other, the gradual increase of
S100B levels from N1 to N4.
The lack of signiﬁcant diﬀerences in the levels of S100B
between the two studied groups in the three perinatal
time points could possibly be attributed to the brain-
sparing phenomenon in cases of IUGR that ensures nutrient
supply to vital organs [60, 61]. Thus, glial cells, mainly
producing S100B, remain unaﬀected by malnutrition [57].
Alternatively, Florio et al. documented increased levels of
S100B in urine samples from IUGR neonates, with highest
levels in those with abnormal neurological outcome [62].
Indeed, S100B is also a marker of hypoxia-induced brain
damage [29, 62]. Nevertheless, the IUGR group in this study
consisted of asymmetrical IUGR babies, with good Apgar
scores at birth and no neurologic sequelae in the short term,
whatsoever.
Furthermore, this study showed that in the IUGR
group, UC PAI-1 positively correlated with maternal age.
Previous studies [63, 64] have reported signiﬁcantly higher
placental PAI-1 levels in IUGR pregnancies with or without
preeclampsia. Taken that older gravidas are at increased
risk of IUGR pregnancies complicated by preeclampsia and
abnormal placentation [65], the above ﬁnding could be
justiﬁed.
On the other hand, controversial reports in the liter-
ature also associate very young maternal age groups with
preeclampsia [66–72]. Nevertheless, the present study did
not comprise in the IUGR group such individuals, since the
age range of the included mothers was 24–38 years.
The positive correlation of maternal and fetal cortisol
levels found in both groups of our study is probably due to
placental transfer [73, 74].
As cortisol has a well-known anti-inﬂammatory eﬀect,
the negative correlations of MS cortisol with UC PAI-1, as
wellasUCcortisolwithMSS100B,UCS100B,andUCPAI-1
in the IUGR group (Table 2), further enhance the hypothesis
for the inﬂammation-mediating role of S100B and PAI-
1. Besides, studies have also documented the reduction of
S100B in the presence of corticosteroids [75, 76].
In conclusion, the absence of diﬀerence in hs-CRP
and PAI-1 levels, between IUGR cases and AGA controls,
possibly indicates an accentuated secretion of these markers
from the adipose tissue in the former, who despite their
lower birth weight, bear a relatively increased amount of
visceral fat as compared to the latter. On the other hand,
the lack of diﬀerence in S100B levels between these two
groups possibly reﬂects the brain-sparing eﬀect occurring
in IUGR cases. Moreover, cortisol remains a major anti-
inﬂammatory compound that counteracts the eﬀect of the
above mentioned inﬂammatory markers. Thus, our ﬁndings
could probably support the concept of aseptic inﬂammation
inIUGRfetusesandneonates.However,implication ofother
inﬂammation-related mechanisms, common in the IUGR
state (e.g. preeclampsia) cannot be excluded.
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